
Suzanne Louise Topalian MD
Surgical Oncology (Other than Breast)
Professor of Surgery, Professor of Oncology, Johns Hopkins University
Join to View Full Profile
1800 Orleans StreetBaltimore, MD 21287
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Suzanne Topalian, MD is a general surgeon in Baltimore, Maryland. She is currently licensed to practice medicine in Maryland. She is affiliated with Johns Hopkins Hospital and is a Professor of Surgery at Johns Hopkins University.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1987 - 1989
Clinical Center at the National Institutes of HealthResidency, Surgery, 1985 - 1986
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Surgery, 1983 - 1985
Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Surgery, 1982 - 1983
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Surgery, 1979 - 1982
Tufts University School of MedicineClass of 1979
Certifications & Licensure
MD State Medical License 2006 - 2027
Publications & Presentations
PubMed
- 5 citationsNivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II...Shailender Bhatia, Suzanne L Topalian, William Sharfman, Tim Meyer, Neil Steven
Journal of Clinical Oncology. 2025-03-20 - 4 citationsPooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.Georgina V Long, James Larkin, Dirk Schadendorf, Jean-Jacques Grob, Christopher D Lao
Journal of Clinical Oncology. 2025-03-10 - 3 citationsA minimal gene set characterizes TIL specific for diverse tumor antigens across different cancer types.Zhen Zeng, Tianbei Zhang, Jiajia Zhang, Shuai Li, Sydney Connor
Nature Communications. 2025-02-03
Press Mentions
Tip Sheet: Johns Hopkins Kimmel Cancer Center Researchers to Present at Asco Annual MeetingMay 26th, 2023
Hopkins Immunotherapy Researchers Named Fellows of the SITC Academy of Immuno-OncologySeptember 19th, 2022
Dragonfly Therapeutics Expands Leadership Team with Chief Operating Officer and Also Strengthens Scientific Advisory BoardNovember 24th, 2020- Join now to see all
Grant Support
- PD-1/PD-L1 modulation in cancer therapyJOHNS HOPKINS UNIVERSITY2010–2026









